JP2017530954A5 - - Google Patents

Download PDF

Info

Publication number
JP2017530954A5
JP2017530954A5 JP2017511942A JP2017511942A JP2017530954A5 JP 2017530954 A5 JP2017530954 A5 JP 2017530954A5 JP 2017511942 A JP2017511942 A JP 2017511942A JP 2017511942 A JP2017511942 A JP 2017511942A JP 2017530954 A5 JP2017530954 A5 JP 2017530954A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
troponin
use according
disease
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017511942A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017530954A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/069341 external-priority patent/WO2016030323A1/en
Publication of JP2017530954A publication Critical patent/JP2017530954A/ja
Publication of JP2017530954A5 publication Critical patent/JP2017530954A5/ja
Pending legal-status Critical Current

Links

JP2017511942A 2014-08-26 2015-08-24 トロポニンのエラスターゼから独立した増加と関連する障害のためのエラフィンの使用 Pending JP2017530954A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102014216985.2 2014-08-26
DE102014216985 2014-08-26
PCT/EP2015/069341 WO2016030323A1 (en) 2014-08-26 2015-08-24 Use of elafin for disorders associated with elastase independent increase in troponin

Publications (2)

Publication Number Publication Date
JP2017530954A JP2017530954A (ja) 2017-10-19
JP2017530954A5 true JP2017530954A5 (enExample) 2019-01-24

Family

ID=54011022

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017511942A Pending JP2017530954A (ja) 2014-08-26 2015-08-24 トロポニンのエラスターゼから独立した増加と関連する障害のためのエラフィンの使用

Country Status (4)

Country Link
US (5) US20180221462A1 (enExample)
EP (1) EP3185892B1 (enExample)
JP (1) JP2017530954A (enExample)
WO (1) WO2016030323A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190060506A1 (en) * 2017-08-22 2019-02-28 The Board Of Trustees Of The Leland Stanford Junior University Elafin Incorporated Biomaterials for the Treatment of Chronic Tissue Ulcers
US20230405078A1 (en) * 2020-03-26 2023-12-21 The Regents Of The University Of California Detection and treatment of intestinal fibrosis
WO2023141237A1 (en) * 2022-01-20 2023-07-27 Cell and Molecular Tissue Engineering, LLC Methods and products to detect, minimize and treat trap-related tissue reactions and tissue injury associated with medical devices

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043308A2 (en) * 1998-02-27 1999-09-02 Marlene Rabinovitch Treating pulmonary hypertension through tenascin suppression and elastase inhibition
MXPA04010560A (es) * 2002-04-25 2005-08-15 Scripps Research Inst Tratamiento y prevencion de condiciones pulmonares.
GB201003559D0 (en) * 2010-03-03 2010-04-21 Proteo Biotech Ag Novel use of elafin

Similar Documents

Publication Publication Date Title
Nagai et al. Urgent Management of Rapid Heart Rate in Patients With Atrial Fibrillation/Flutter and Left Ventricular Dysfunction–Comparison of the Ultra-Short-Acting β1-Selective Blocker Landiolol With Digoxin (J-Land Study)–
Greenberg et al. Postoperative atrial fibrillation following cardiac surgery: a persistent complication
Ding et al. Mdivi-1 alleviates cardiac fibrosis post myocardial infarction at infarcted border zone, possibly via inhibition of Drp1-Activated mitochondrial fission and oxidative stress
Vives et al. Cardiac surgery-associated acute kidney injury
Picariello et al. The impact of hypertension on patients with acute coronary syndromes
DK1556025T3 (da) Præparater omfattende vitamin K til forebyggelse af hypertension, venstre ventrikulær hypertrofi, kongestiv hjertesvigt, myokardial infarkt, slagtilfælde og koronar hjertesygdom ved at forebygge alders-relateret afstivning af arterier
FI3562487T3 (fi) Metalloentsyymi-inhibiittoriyhdisteitä
JP2015512387A5 (enExample)
Gultekin et al. Microtubule inhibition therapy by colchicine in severe myocarditis especially caused by Epstein-Barr and cytomegalovirus co-infection during a two-year period: a novel therapeutic approach
JP2020511416A5 (enExample)
Flu et al. Perioperative cardiac damage in vascular surgery patients
Barman Proarrhythmic effects of antiarrhythmic drugs: case study of flecainide induced ventricular arrhythmias during treatment of atrial fibrillation
WO2022240379A3 (en) A stable pharmaceutical composition comprising selexipag
JP2007518769A5 (ja) 内皮前駆細胞の刺激並びに臓器の再生及び末端器官障害の進行の抑制のための低用量エリスロポエチンの使用
Damman et al. Pathophysiological mechanisms contributing to renal dysfunction in chronic heart failure
DK1728507T3 (da) Anvendelse af vitamin K for at omvende forkalkning af blodkar
Alyavi et al. Treatment of stable angina pectoris: focus on the role of calcium antagonists and ACE inhibitors
JP2010522774A5 (enExample)
Mahmod et al. Atrial fibrillation as a complication of dengue hemorrhagic fever: non-self-limiting manifestation
Zhou et al. Natakalim improves post-infarction left ventricular remodeling by restoring the coordinated balance between endothelial function and cardiac hypertrophy
WO2007047882A3 (en) Combination of cxcr4 antagonist and morphogen to increase angiogenesis
Coppolino et al. Endothelial progenitor cells at the interface of chronic kidney disease: from biology to therapeutic advancement
Łopatowska et al. Management of patients with valvular and non-valvular atrial fibrillation in Poland: Results from Reference Cardiology University Center
Bianchi et al. Extracorporeal life support for post-cardiotomy acute right ventricular failure: a retrospective observational multicenter study
Momomura Acute rate control in atrial fibrillation with left ventricular dysfunction